

14. Týčková I, Sulková SD, Štěpánková J, et al. Molecular patterns of diffuse and nodular parathyroid hyperplasia in long-term hemodialysis. *Am J Physiol Endocrinol Metab* 2016; 311: E720–E729.

15. Silver J, Kilav R, Naveh-Many T. Mechanisms of secondary hyperparathyroidism. *Am J Physiol Renal Physiol* 2002; 283: F367–F376.

16. Komaba H, Fukagawa M. Phosphate—a poison for humans? *Kidney Int* 2016; 90: 753–763.

17. Vanholder R, Argiles A, Baummeister U, et al. Uremic toxicity: present state of the art. *Int J Artif Organs* 2001; 24: 695–725.

18. Hyšpler R, Tichá A, Šafránek R, et al. Indoxyl Sulfate Elimination in Renal Replacement Therapy: Influence of Citrate- versus Acetate-Buffering Component during Bicarbonate Dialysis. *Dis Markers* 2018; 15: 3985–3986.

19. Ritter CS, Slatopolsky E. Phosphate Toxicity in CKD: The Killer among Us. *Clin J Am Soc Nephrol* 2016; 11: 1088–1100.

20. Moe SM. Calcium as a cardiovascular toxin in CKD-MBD. *Bone* 2017; 100: 94–99.

21. Lynch K, Lynch R, Curhan GC, et al. Prescribed dietary phosphate restriction and survival among hemodialysis patients. *Clin J Am Soc Nephrol* 2011; 6: 620–629.

22. Sekercioglu N, Thabane L, Diaz-Martinez JP, et al. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. *PLoS One* 2016; 11(6): e0156891.

23. Floege J. Phosphate binders in chronic kidney disease: a systematic review of recent data. *J Nephrol* 2016; 29: 329–340.

24. Isakova T, Ix JH, Sprague SM, et al. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. *J Am Soc Nephrol* 2015; 26: 2328–2339.

25. Mehta R, Isakova T. Continued search for therapies to favourably modify phosphate and FGF-23 levels in CKD. *Clin J Am Soc Nephrol* 2017; 12: 1911–1913.

26. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. *Kidney Int* 2017; 92: 26–36.

27. Cozzolino M. CKD-MBD KDIGO guidelines: how difficult is reaching the “target”? *Clin Kidney J* 2018; 11: 70–72.

28. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl* 2017; 7: 1–59.

29. Lopot F, Švára F, Polakovič. „Revival domácí dialýzy“. *Aktuality v nefrologii* 2018; 24: 46–55.

30. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2006; 69: 1945–1953.

31. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). *Kidney Int* 2009; 76: (Suppl. 113): S3–S130.

32. Brunerová L, Palicka V, Sulkova SD. Commentary on management of osteoporosis in advanced CKD: common view of a nephrologist and a bone specialist. *Endocr Pract* 2019; 25: 193–196.

33. Lau WL, Pai A, Moe SM, et al. Direct effects of phosphate on vascular cell function. *Adv Chronic Kidney Dis* 2011; 18: 105–112.

34. Cozzolino M, Ciceri P, Galassi A. The Key Role of Phosphate on Vascular Calcification. *Toxins* 2019; 11: 213.

35. Disthabanchong S. Phosphate and cardiovascular disease beyond chronic kidney disease and vascular calcification. *Int J Nephrology* 2018; doi.org/10.1155/2018/3152806

36. Razaque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. *Nat Rev Endocrinol* 2009; 5: 611–619.

37. Grabner A, Mazzaferro S, Cianciolo G. Fibroblast Growth Factor 23: Mineral Metabolism and Beyond. *Contrib Nephrol* 2017; 190: 83–95.

38. Rodriguez M, Lorenzo V. Parathyroid hormone, a uremic toxin. *Semin Dial* 2009; 22: 363–368.

39. Navarro-García JA, Fernández-Velasco M, Delgado C, et al. PTH, vitamin D, and the FGF-23-klotho axis and heart: Going beyond the confines of nephrology. *Eur J Clin Invest* 2018; 48: doi: 10.1111/eci.12902.

40. Gutiérrez OM, Mannstadt M, Isakova T. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. *N Engl J Med* 2008; 359: 584–592.

41. Agarwal I, Ide N, Ix JH. Fibroblast growth factor-23 and cardiac structure and function. *J Am Heart Assoc* 2014; 3: e000584.


42. Ho LY, Wong PN, Sin HK, et al. Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. *BMC Nephrol* 2017; 18: 12.

43. Wang J, Zhou JJ, Robertson GR, et al. Vitamin D in Vascular Calcification: A Double-Edged Sword? *Nutrients* 2018; 10: pii: E652.

44. Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. *N Engl J Med* 2018; 378: 1704–1714.

45. Nigwekar SU, Kroschinsky D, Nazarian RM. Calciphylaxis: risk factors, diagnosis, and treatment. *Am J Kidney Dis* 2015; 66: 133–146.

# Víte, že listovačky časopisu **Klinická farmakologie a farmacie** jsou volně dostupné on-line?



V posledních číslech najdete tato hlavní témata:

- Farmakoterapie v anesteziologii (2/2019)
- Oftalmologie (1/2019)
- Pneumologie (4/2018)
- Gastroenterologie (3/2018)
- Nefrologie (1/2018)

... a mnoho článků z jiných oblastí medicíny a farmacie

[www.klinickafarmakologie.cz](http://www.klinickafarmakologie.cz)



Mohou být přínosné i pro vás...